Business
Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, and Dilon Technologies, Inc., a medical device manufacturer, today announced that the companies have entered into an agreement whereby Xtant has acquired exclusive U.S. distribution rights to Dilon's HEMOBLAST® Bellows for high-performance hemostasis following certain surgical procedures.
About this update from Xtant Medical Holdings, Inc.
[{"type":"text","content":"Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products ","length":188,"tagName":"p","attribs":{}},{"type":"text","content":"BELGRADE, Mont. and NEWPORT NEWS, Va., April 13, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, and Dilon Technologies, Inc., a medical device manufacturer, today announced that the companies have entered into an agreement whereby Xtant has acquired exclusive U.S. distribution rights to Dilon's HEMOBLAST® Bellows for high-performance hemostasis following certain surgical procedures.","length":528,"tagName":"p"},{"type":"image","alt":"Xtant Medical Logo (PRNewsfoto/Xtant Medical Holdings, Inc.)","displaySize":"","headline":null,"caption":"Xtant Medical Logo (PRNewsfoto/Xtant Medical Holdings, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":260,"url":"https://media.zenfs.com/en/prnewswire.com/46c9cfa2f4f133a34a9e506f23e2f7a1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1PjsWogK_MOUVYgyWRr7tg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ1OA--/https://media.zenfs.com/en/prnewswire.com/46c9cfa2f4f133a34a9e506f23e2f7a1","width":400,"height":260}},"href":"https://mma.prnewswire.com/media/2725938/XTNT_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Sean Browne, President and CEO of Xtant Medical, stated, "We are excited to partner with Dilon Technologies to bring HEMOBLAST, a highly complementary hemostatic technology, to a broader group of surgeons. This agreement expands our portfolio with a unique and versatile hemostatic solution while also significantly bolstering our own commercial capabilities with the integration of Dilon's approximately 20-person U.S. sales team into our organization. With our broadened product offering and enhanced reach and sales capabilities, we believe we can better address the comprehensive needs of surgeons and patients alike while meaningfully expanding our addressable market."","length":688,"tagName":"p"},{"type":"text","content":"George Makhoul, CEO of Dilon Technologies, stated, "HEMOBLAST is highly differentiated in th...